NCT06170827View on ClinicalTrials.gov

Study to Evaluate the AIO-001 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions

Respiratory Disease

Interventions

DRUG

AIO-001

AIO-001 Solution for SC injection.

Trial Locations (1)

4006

Q-Pharm Pty Ltd, Herston

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Aiolos Bio, Inc., a GSK Company

UNKNOWN

lead

Syneos Health

OTHER